What is the IRON stock price?

Disc Medicine, Inc. (IRON) latest quote: $79.29, as of 10/27/26 1:54 PM ET. Prices on Cylvex may be delayed.

How many analyst price targets for IRON were reached?

9 of 17 published price targets for IRON were reached within 12 months (53% reached); 18 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on IRON?

12 firms have published price targets or ratings on IRON that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

IRON

Disc Medicine, Inc. · NASDAQ

News

3 latest

Tue, Oct 20

GlobeNewswire Inc.10/21/26

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 6 million shares at $75 per share, generating $450 million in gross proceeds. The company plans to use the funds for research and clinical development of product candidates, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and general corporate purposes. The offering is expected to close on October 22, 2026.

Mon, Oct 5

GlobeNewswire Inc.10/5/26

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence.

Mentions IRON

Sun, Oct 18

GlobeNewswire Inc.10/18/26

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine announced it will host a webcast on October 19, 2026 to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. Bitopertin is an investigational oral GlyT1 inhibitor designed to modulate heme biosynthesis and has potential to be the first disease-modifying therapy for erythropoietic porphyrias.

Headlines link to the publisher. Not investment advice.